## Mariona Graupera

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9387683/publications.pdf

Version: 2024-02-01

117571 149623 5,457 57 34 56 citations g-index h-index papers 64 64 64 9135 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Behavioural immune landscapes of inflammation. Nature, 2022, 601, 415-421.	13.7	53
2	Angiocrine polyamine production regulates adiposity. Nature Metabolism, 2022, 4, 327-343.	5.1	31
3	The onset of PI3Kâ€related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib. EMBO Molecular Medicine, 2022, 14, .	3.3	19
4	A junctional PACSIN2/EHD4/MICAL-L1 complex coordinates VE-cadherin trafficking for endothelial migration and angiogenesis. Nature Communications, 2021, 12, 2610.	5.8	23
5	The loss of DHX15 impairs endothelial energy metabolism, lymphatic drainage and tumor metastasis in mice. Communications Biology, 2021, 4, 1192.	2.0	5
6	Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer. Journal of Experimental Medicine, 2020, 217, .	4.2	19
7	Editorial: Endothelial Dynamics in Health and Disease. Frontiers in Physiology, 2020, 11, 611117.	1.3	O
8	Phosphoinositide 3-Kinase–Regulated Pericyte Maturation Governs Vascular Remodeling. Circulation, 2020, 142, 688-704.	1.6	29
9	Blockade of VEGF-C signaling inhibits lymphatic malformations driven by oncogenic PIK3CA mutation. Nature Communications, 2020, 11, 2869.	5.8	59
10	Developmental and Tumor Angiogenesis Requires the Mitochondria-Shaping Protein Opa1. Cell Metabolism, 2020, 31, 987-1003.e8.	7.2	101
11	Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer. Cell Reports, 2019, 28, 2156-2168.e5.	2.9	129
12	Antitumor Effects of Anti-Semaphorin 4D Antibody Unravel a Novel Proinvasive Mechanism of Vascular-Targeting Agents. Cancer Research, 2019, 79, 5328-5341.	0.4	21
13	PIK3CA mutations in vascular malformations. Current Opinion in Hematology, 2019, 26, 170-178.	1.2	38
14	Revisiting PI3-kinase signalling in angiogenesis. Vascular Biology (Bristol, England), 2019, 1, H125-H134.	1.2	20
15	ALK1 Loss Results in Vascular Hyperplasia in Mice and Humans Through PI3K Activation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1216-1229.	1.1	<b>7</b> 5
16	A Role for CXCR4 in Peritoneal and Hematogenous Ovarian Cancer Dissemination. Molecular Cancer Therapeutics, 2018, 17, 532-543.	1.9	28
17	Endothelial cell rearrangements during vascular patterning require PI3-kinase-mediated inhibition of actomyosin contractility. Nature Communications, 2018, 9, 4826.	5.8	53
18	Endothelial Cells: New Players in Obesity and Related Metabolic Disorders. Trends in Endocrinology and Metabolism, 2018, 29, 781-794.	3.1	59

#	Article	IF	Citations
19	Integrative analysis of transcriptomics and clinical data uncovers the tumor-suppressive activity of MITF in prostate cancer. Cell Death and Disease, 2018, 9, 1041.	2.7	14
20	DYRK1A Kinase Positively Regulates Angiogenic Responses in Endothelial Cells. Cell Reports, 2018, 23, 1867-1878.	2.9	34
21	Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. Oncogene, 2017, 36, 2737-2749.	2.6	34
22	Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling. Nature Communications, 2017, 8, 1773.	5.8	54
23	Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action. Targeted Oncology, 2017, 12, 19-35.	1.7	77
24	The $TGF\hat{l}^2$ pathway stimulates ovarian cancer cell proliferation by increasing IGF1R levels. International Journal of Cancer, 2016, 139, 1894-1903.	2.3	53
25	PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasia. Nature Communications, 2016, 7, 13650.	5.8	136
26	Therapeutic Benefit of Selective Inhibition of p110 $\hat{l}$ ± PI3-Kinase in Pancreatic Neuroendocrine Tumors. Clinical Cancer Research, 2016, 22, 5805-5817.	3.2	35
27	The metabolic co-regulator PGC1α suppresses prostate cancer metastasis. Nature Cell Biology, 2016, 18, 645-656.	4.6	176
28	Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients. Cell Reports, 2016, 15, 1134-1143.	2.9	96
29	Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy. Cancer Discovery, 2016, 6, 1090-1105.	7.7	217
30	Somatic activating mutations in <i>Pik3ca</i> cause sporadic venous malformations in mice and humans. Science Translational Medicine, 2016, 8, 332ra43.	5.8	138
31	Class I PI-3-Kinase Signaling Is Critical for Bone Formation Through Regulation of SMAD1 Activity in Osteoblasts. Journal of Bone and Mineral Research, 2016, 31, 1617-1630.	3.1	24
32	Sequential Functions of CPEB1 and CPEB4 Regulate Pathologic Expression of Vascular Endothelial Growth Factor and Angiogenesis in Chronic Liver Disease. Gastroenterology, 2016, 150, 982-997.e30.	0.6	73
33	Novel Role for p $110\hat{1}^2$ PI 3-Kinase in Male Fertility through Regulation of Androgen Receptor Activity in Sertoli Cells. PLoS Genetics, 2015, 11, e1005304.	1.5	35
34	cKit Lineage Hemogenic Endothelium-Derived Cells Contribute to Mesenteric Lymphatic Vessels. Cell Reports, 2015, 10, 1708-1721.	2.9	207
35	PI3K at the crossroads of tumor angiogenesis signaling pathways. Molecular and Cellular Oncology, 2015, 2, e975624.	0.3	29
36	PTEN mediates Notch-dependent stalk cell arrest in angiogenesis. Nature Communications, 2015, 6, 7935.	5.8	86

#	Article	IF	CITATIONS
37	The PDGFRβ–AKT Pathway Contributes to CDDP-Acquired Resistance in Testicular Germ Cell Tumors. Clinical Cancer Research, 2014, 20, 658-667.	3.2	55
38	Regulation of angiogenesis by PI3K signaling networks. Experimental Cell Research, 2013, 319, 1348-1355.	1.2	94
39	ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor. International Journal of Cancer, 2013, 133, 235-246.	2.3	16
40	Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors. BMC Cancer, 2013, 13, 382.	1.1	21
41	Metronomic chemotherapy following the maximum tolerated dose is an effective antiâ€tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells. International Journal of Cancer, 2013, 133, 2464-2472.	2.3	76
42	Inhibition of the p110 $\hat{l}_{\pm}$ isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis. Journal of Experimental Medicine, 2013, 210, 1937-1945.	4.2	56
43	Inhibition of the p $110\hat{l}\pm$ isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis. Journal of Cell Biology, 2013, 202, 2027OIA99.	2.3	0
44	Crosstalk Between Reticular Adherens Junctions and Platelet Endothelial Cell Adhesion Molecule-1 Regulates Endothelial Barrier Function. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, e90-102.	1.1	61
45	Integrin-dependent and -independent functions of astrocytic fibronectin in retinal angiogenesis. Development (Cambridge), 2011, 138, 4451-4463.	1.2	116
46	The emerging mechanisms of isoform-specific PI3K signalling. Nature Reviews Molecular Cell Biology, 2010, 11, 329-341.	16.1	1,491
47	Angiogenesis selectively requires the p110 $\hat{l}\pm$ isoform of Pl3K to control endothelial cell migration. Nature, 2008, 453, 662-666.	13.7	459
48	Largeâ€conductance calciumâ€activated potassium channels modulate vascular tone in experimental cirrhosis. Liver International, 2008, 28, 566-573.	1.9	6
49	Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. Journal of Hepatology, 2007, 46, 1040-1046.	1.8	203
50	Identification and Functional Characterization of the Hepatic Stellate Cell CD38 Cell Surface Molecule. American Journal of Pathology, 2007, 170, 176-187.	1.9	44
51	Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 8959-8964.	3.3	47
52	Sinusoidal endothelial COX-1-derived prostanoids modulate the hepatic vascular tone of cirrhotic rat livers. American Journal of Physiology - Renal Physiology, 2005, 288, G763-G770.	1.6	65
53	Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. Hepatology, 2003, 37, 172-181.	3.6	126
54	Left ventricular hypertrophy in rats with biliary cirrhosis. Hepatology, 2003, 38, 589-598.	3.6	46

#	Article	IF	CITATIONS
55	Cyclooxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers. Journal of Hepatology, 2003, 39, 515-521.	1.8	68
56	Acute propranolol administration effectively decreases portal pressure in patients with TIPS dysfunction. Gut, 2003, 52, 130-133.	6.1	22
57	5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: A possible role of cysteinyl-leukotrienes. Gastroenterology, 2002, 122, 387-393.	0.6	96